Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Corcept Therapeutics Inc CORT

Healthcare
Corcept Therapeutics Incorporated is a commercial-stage company, which is engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has... see more

Recent & Breaking News (NDAQ:CORT)

Levi & Korsinsky, LLP Notifies Shareholders of Corcept Therapeutics Incorporated (CORT) an Upcoming Claims Deadline in a Class Action Settlement

Accesswire 1 hour ago

Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update

GlobeNewswire 21 hours ago

Corcept Completes Enrollment in Phase 4 CATALYST Trial

GlobeNewswire 3 days ago

Levi & Korsinsky, LLP Notifies Shareholders of Corcept Therapeutics Incorporated (CORT) an Upcoming Claims Deadline in a Class Action Settlement

Accesswire 7 days ago

Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call

GlobeNewswire 7 days ago

Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing's Syndrome

GlobeNewswire 10 days ago

Levi & Korsinsky, LLP Notifies Shareholders of Corcept Therapeutics Incorporated (CORT) an Upcoming Claims Deadline in a Class Action Settlement

Accesswire April 18, 2024

Levi & Korsinsky, LLP Notifies Shareholders of Corcept Therapeutics Incorporated (CORT) an Upcoming Claims Deadline in a Class Action Settlement

Accesswire April 16, 2024

Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)

GlobeNewswire April 15, 2024

Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer

GlobeNewswire April 8, 2024

Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing's Syndrome

GlobeNewswire April 1, 2024

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update

GlobeNewswire February 15, 2024

Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial

GlobeNewswire February 15, 2024

Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results, Provide Corporate Update and Host Conference Call

GlobeNewswire February 8, 2024

Corcept Appoints Roberto Vieira as President, Oncology

GlobeNewswire January 29, 2024

Corcept Therapeutics Provides Financial Update and Announces Stock Repurchase Program

GlobeNewswire January 8, 2024

Court Finds Corcept Therapeutics' Patents Not Infringed

GlobeNewswire January 2, 2024

Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update

GlobeNewswire November 1, 2023

Corcept Appoints Monica Tellado as President, Emerging Markets

GlobeNewswire November 1, 2023

Corcept Initiates MONARCH - A Phase 2b Trial in Non-Alcoholic Steatohepatitis (NASH)

GlobeNewswire October 26, 2023